Activation of PDE2A moderates pathologically high cAMP/PKA responses to dopamine in dyskinetic mice
Neurobiology of Disease · 2025
DOI: 10.1016/j.nbd.2025.106968 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurobiology of Disease, 2025. Verfasst von Ségolène Bompierre und 4 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, CNRS, Inserm, Institut de Biologie Paris Seine (IBPS), Center for Neuroscience at Sorbonne Université (NeuroSU), 75005, Paris, F…. Hauptthemen laut MEDLINE: Cyclic Nucleotide Phosphodiesterases, Type 2, Cyclic AMP-Dependent Protein Kinases, Cyclic AMP, Dopamine. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: French Association for Parkinson's Disease, French National Research Agency.
Abstract (Originalsprache)
Dopamine depletion in Parkinson's disease (PD) leads to severe motor and cognitive disturbances. While L-DOPA replacement therapy efficiently alleviates the motor symptoms, it leads to long-term complications, notably dyskinesia. These deregulations are closely associated with an exacerbated cAMP/PKA signaling and alterations in striatal plasticity. In this study we used genetically encoded biosensors to monitor cAMP and PKA signals in the 6-OHDA mouse model of Parkinson's disease. In these mice cAMP levels and PKA signaling were markedly up-regulated. We observed that stimulation of the cGMP signaling by a NO donor, DEANO, efficiently down-regulated the amplitude of these hypersensitive responses and this regulatory effect was mediated by PDE2A. Indeed, the stimulation of PDE2A by cGMP was found to efficiently reduce the excessive cAMP/PKA signaling triggered by D1 receptor stimulation, and this, despite unaltered PDE2A expression. These findings strongly suggest that boosting PDE2A activity in the striatum would be of therapeutic value to moderate the excessive cAMP/PKA responses and mitigate the long-term changes in striatal neurons associated with the adverse effects of L-DOPA treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sorbonne Université, CNRS, Inserm, Institut de Biologie Paris Seine (IBPS), Center for Neuroscience at Sorbonne Université (NeuroSU), 75005, Paris, France. Electronic address: segolene.bompierre@donders.ru.nl.
- Sorbonne Université, CNRS, Inserm, Institut de Biologie Paris Seine (IBPS), Center for Neuroscience at Sorbonne Université (NeuroSU), 75005, Paris, France. Electronic address: yapoced@yahoo.fr.
- Sorbonne Université, CNRS, Inserm, Institut de Biologie Paris Seine (IBPS), Center for Neuroscience at Sorbonne Université (NeuroSU), 75005, Paris, France. Electronic address: regis.blaise@sorbonne-universite.fr.
- Sorbonne Université, CNRS, Inserm, Institut de Biologie Paris Seine (IBPS), Center for Neuroscience at Sorbonne Université (NeuroSU), 75005, Paris, France; IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France. Elec…
- Sorbonne Université, CNRS, Inserm, Institut de Biologie Paris Seine (IBPS), Center for Neuroscience at Sorbonne Université (NeuroSU), 75005, Paris, France. Electronic address: liliana.ribeiro_vivas_de_castro@sorbonne-un…
Förderung
- French Association for Parkinson's Disease
- French National Research Agency
Zitieren
APA
Bompierre, S., Yapo, C., Blaise, R., Vincent, P., & Castro, L. R. V. (2025). Activation of PDE2A moderates pathologically high cAMP/PKA responses to dopamine in dyskinetic mice. Neurobiology of Disease. https://doi.org/10.1016/j.nbd.2025.106968
Vancouver
Bompierre S, Yapo C, Blaise R, Vincent P, Castro LRV. Activation of PDE2A moderates pathologically high cAMP/PKA responses to dopamine in dyskinetic mice. Neurobiology of Disease. 2025. doi:10.1016/j.nbd.2025.106968
BibTeX
@article{Bompierre2025,
author = {Bompierre, Ségolène and Yapo, Cédric and Blaise, Régis and Vincent, Pierre and Castro, Liliana R V},
title = {Activation of PDE2A moderates pathologically high cAMP/PKA responses to dopamine in dyskinetic mice},
journal = {Neurobiology of Disease},
year = {2025},
doi = {10.1016/j.nbd.2025.106968}
}
EUVIMED